SK Biopharmaceuticals is one of SK Group’s core units
Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut on a conferencel call of SK Biopharmaceuticals Co. on Friday to unveil the drug maker’s medium-to-long-term business roadmap to analysts online.
It was the first time for the junior Chey, the third-generation of the family-run conglomerate, to give a presentation to analysts and directly take their questions that took about one hour.
Since being promoted to vice president of SK Biopharmaceuticals in December last year, the 35-year-old executive told analysts that the company aimed to build its leadership in the global radiopharmaceutical therapy (RPT) market by around 2027 by bolstering the pipeline of preclinical drug candidates.
“We’ll secure two additional RPT candidates next year” she said, adding that the core arm of the country’s No. 2 business group is looking to expand into the diagnostic agent market.
The youngest executive of SK Group oversees SK Pharmaceuticals’ in-licensing deals with drug candidate developers. Particuarly, she is tightening her grip on RPT, which analysts said would test her management capabilities as a third-generation leader of the conglomerate.
SK Biopharm Vice President Chey Yoon-chung
She spearheaded the $571.5 million licensing deal with Full-Life Technologies to secure its first RPT candidate.
In July, it signed an agreement with the German radiotherapeutics company to join hands to develop and commercialize Full-Life’s RPT compound, dubbed FL-091, into an anti-cancer treatment.
FL-091 is a small-molecule radioligand vector designed to deliver targeted radiation therapy to cancer cells by binding specifically to NTSR1, a receptor protein. The NTSRI is overexpressed in various types of solid tumors, including colorectal cancer, prostate cancer, and pancreatic cancer.
“FL-091 has the potential to be a blockbuster drug,” said Chey. “It demonstrates enhanced binding affinity (to NTSR1), more than 10 times stronger than that of competing drugs, so it has the high potential to be a best-in-class drug.”
SK plans to carry out its preclinical tests in South Korea and then Phase 1 clinical trial at the end of next year.
It will submit investigational new drug (IND) applications to the US and South Korea in the second half of next year to administer the RPT candidate for clinical trials. It aims to release it as a novel therapy around 2034.
SK Pharmaceuticals’ researchers (Courtesy of SK Pharmaceuticals)
Chey joined SK Biopharmaceuticals in 2017. With a Master’s in biomedical informatics at Stanford University, she has been leading the company’s strategy team since January 2023.
In addition to RPT, SK Biopharmaceuticals sets its sights on targeted protein degradation (TPD) and cell and gene therapies (CGT) to develop next-generation anti-cancer treatments.
It will boost its piepeline of drug candidates with the cash generated from Cenobamate, its first commercialized drug. The epilepsy treatment received the green light from the US Food and Drug Administration (FDA) in 2019.
By 2032, SK expects Cenobamate, sold under the Xcopri brand in the US, to generate 4 trillion wo ($3 billion) n in accumulated cash.
By Jeong Min Nam
peux@hankyung.com
Yeonhee Kim edited this article
